CXCR2 Levels Correlate with Immune Infiltration and a Better Prognosis of Triple-Negative Breast Cancers

Prognostic significance of PD-L1-positive cancer-associated fibroblasts in patients with triple-negative breast cancer

(2021) Katsuhiro Yoshikawa et al.   BMC CANCER

Clinicopathological Correlates of γδ T Cell Infiltration in Triple-Negative Breast Cancer

(2021) Florence Boissière-Michot et al.   Cancers

BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer

(2020) William Jacot et al.   Cancers

Co-Expression of Androgen Receptor and Cathepsin D Defines a Triple-Negative Breast Cancer Subgroup with Poorer Overall Survival

(2020) Hanane Mansouri et al.   Cancers

PD-L1 protein expression on both tumor cells and macrophages are associated with response to neoadjuvant durvalumab in triple negative breast cancer (TNBC)

(2020) Fahad Shabbir Ahmed et al.   CLINICAL CANCER RESEARCH

Prognostic Value of CXCR2 in Breast Cancer

(2020) Florence Boissière-Michot et al.   Cancers

Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis

(2020) Zhao-hua Gao et al.   BMC CANCER

Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers

(2019) Sherene Loi et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers

(2018) Séverine Guiu et al.   BRITISH JOURNAL OF CANCER

A guide to chemokines and their receptors

(2018) Catherine E. Hughes et al.   FEBS Journal

Understanding the tumor immune microenvironment (TIME) for effective therapy

(2018) Mikhail Binnewies et al.   NATURE MEDICINE

Immunological differences between primary and metastatic breast cancer

(2018) B Szekely et al.   ANNALS OF ONCOLOGY

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study

(2018) S Adams et al.   ANNALS OF ONCOLOGY

Cancer Inflammation and Cytokines

(2017) Maria Rosaria Galdiero et al.   Cold Spring Harbor Perspectives in Biology

Recent discoveries concerning the tumor - mesenchymal stem cell interactions

(2016) Gwendal Lazennec et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Molecular Classification of Triple-Negative Breast Cancer

(2016) Sung Gwe Ahn et al.   Journal of Breast Cancer

Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes

(2016) Sasha E. Stanton et al.   JAMA Oncology

High incidence of germlineBRCAmutation in patients with ER low-positive/PR low-positive/HER-2neunegative tumors

(2015) Rachel A. Sanford et al.   CANCER

IL-1β produced by aggressive breast cancer cells is one of the factors that dictate their interactions with mesenchymal stem cells through chemokine production

(2015) Pauline Escobar et al.   Oncotarget

CD11b+Ly6G+ cells inhibit tumor growth by suppressing IL-17 production at early stages of tumorigenesis

(2015) Yuhong Liu et al.   OncoImmunology

Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab

(2015) Roberto Salgado et al.   JAMA Oncology

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

(2014) R. Salgado et al.   ANNALS OF ONCOLOGY

Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer

(2014) M. D. Burstein et al.   CLINICAL CANCER RESEARCH

Multiplexed Quantitative Analysis of CD3, CD8, and CD20 Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer

(2014) J. R. Brown et al.   CLINICAL CANCER RESEARCH

Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199

(2014) Sylvia Adams et al.   JOURNAL OF CLINICAL ONCOLOGY

Characterization of an adaptive immune response in microsatellite-instable colorectal cancer

(2014) Florence Boissière-Michot et al.   OncoImmunology

Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer

(2013) S A Quezada et al.   BRITISH JOURNAL OF CANCER

Tumor-Associated Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Breast Cancer Patients

(2013) Hee Jin Lee et al.   Journal of Breast Cancer

A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis

(2012) Swarnali Acharyya et al.   CELL

Adjuvant early breast cancer systemic therapies according to daily used technologies

(2011) W. Jacot et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

Tumor-Infiltrating CD8+ Lymphocytes Predict Clinical Outcome in Breast Cancer

(2011) Sahar M.A. Mahmoud et al.   JOURNAL OF CLINICAL ONCOLOGY

CXCR2-positive neutrophils are essential for cuprizone-induced demyelination: relevance to multiple sclerosis

(2010) LiPing Liu et al.   NATURE NEUROSCIENCE

Chemokines and chemokine receptors: new insights into cancer-related inflammation

(2010) Gwendal Lazennec et al.   TRENDS IN MOLECULAR MEDICINE

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

(2010) M. Elizabeth H. Hammond et al.   Journal of Oncology Practice

CXC Ligand 5 Is an Adipose-Tissue Derived Factor that Links Obesity to Insulin Resistance

(2009) Carine Chavey et al.   Cell Metabolism

Chemokine Signaling via the CXCR2 Receptor Reinforces Senescence

(2008) Juan C. Acosta et al.   CELL